Enliven Therapeutics (ELVN)

• Market cap: $848M
• 1 day: 6.72%
• 5 days: 0.82%
• 1 month: -22.93%
• 3 months: -21.50%
• 6 months: -40.27%
• Year to date: -27.57%
• 1 year: -1.76%
• 5 years: 8.19%
• 10 years: 15.40%
• Sector: Healthcare
• Industry: Biotechnology

About: Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Employees: 62

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

257% more call options, than puts

Call options by funds: $25K | Put options by funds: $7K

100% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 11

80% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 25

10% more funds holding

Funds holding: 102 [Q3] → 112 (+10) [Q4]

0.61% more ownership

Funds ownership: 100.95% [Q3] → 101.56% (+0.61%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 8 [Q3] → 8 (+0) [Q4]

8% less capital invested

Capital invested by funds: $1.22B [Q3] → $1.12B (-$101M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $39 125% upside
• Avg. target: $39 125% upside
• High target: $39 125% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Robert Burns 15% 1-year accuracy 26 / 172 met price target

125% upside $39

Buy Maintained

21 Mar 2025